DS-2969b
Modify Date: 2024-01-22 11:42:55
DS-2969b structure
|
Common Name | DS-2969b | ||
|---|---|---|---|---|
| CAS Number | 2092352-48-0 | Molecular Weight | 428.936 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C17H25ClN6O3S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of DS-2969bDS-2969b (DS 11960558) is a novel orally active GyrB inhibitor, inhibits the supercoiling activity of C. difficile DNA gyrase with IC50 of 20 ng/mL; showes potent in vitro activity against C. difficile clinical isolates with MIC90 of 0.06 μg/mL, 2-, 32-, and 16-fold lower than the MIC90 of fidaxomicin, vancomycin, and metronidazole, respectively; demonstrates excellent in vivo activity against Clostridium difficile (CDI) model. Bacterial Infection Phase 1 Clinical |
| Name | DS-2969b |
|---|
| Description | DS-2969b (DS 11960558) is a novel orally active GyrB inhibitor, inhibits the supercoiling activity of C. difficile DNA gyrase with IC50 of 20 ng/mL; showes potent in vitro activity against C. difficile clinical isolates with MIC90 of 0.06 μg/mL, 2-, 32-, and 16-fold lower than the MIC90 of fidaxomicin, vancomycin, and metronidazole, respectively; demonstrates excellent in vivo activity against Clostridium difficile (CDI) model. Bacterial Infection Phase 1 Clinical |
|---|---|
| References | References 1. Mathur T, et al. Antimicrob Agents Chemother. 2018 Feb 12. pii: AAC.02157-17. 2. Vandell AG, et al. Antimicrob Agents Chemother. 2018 Feb 12. pii: AAC.02537-17. View Related Products by Target Bacterial Bacterial Infection |
| Molecular Formula | C17H25ClN6O3S |
|---|---|
| Molecular Weight | 428.936 |